Article ; Online: Mechanism of TLR4-Mediated Anti-Inflammatory Response Induced by Exopolysaccharide from the Probiotic Bacillus subtilis.
Journal of immunology (Baltimore, Md. : 1950)
2023 Volume 211, Issue 8, Page(s) 1232–1239
Abstract: Intestinal inflammatory diseases affect millions of people worldwide, and one class of drugs showing promise toward treatment of several inflammatory diseases is probiotics. Numerous studies have been performed using probiotics to prevent and treat ... ...
Abstract | Intestinal inflammatory diseases affect millions of people worldwide, and one class of drugs showing promise toward treatment of several inflammatory diseases is probiotics. Numerous studies have been performed using probiotics to prevent and treat intestinal inflammatory diseases. Most of these studies used intact bacteria, and neither the active molecule nor the molecular mechanisms by which they affect immune responses are known. We have shown that the probiotic Bacillus subtilis is anti-inflammatory and can protect mice from acute colitis induced by the enteric pathogen Citrobacter rodentium. We identified and purified the active molecule, exopolysaccharide (EPS), and showed that it protects mice from C. rodentium-induced colitis by inducing anti-inflammatory M2 macrophages or inhibitory dendritic cells (DCs), both of which inhibit excessive T cell responses. We showed previously that EPS affects macrophages and DCs in a TLR4-dependent manner, and in the current study we asked how EPS induces these anti-inflammatory cells and how they function to inhibit T cells. By investigating the signaling downstream of TLR4 that leads to acquisition of inhibitory properties of macrophages and DCs, we found that EPS induces expression of the inhibitory molecule IDO in bone marrow-derived DCs, and that inhibition of T cell proliferation by IDO-expressing bone marrow-derived DCs utilizes the kynurenine/aryl hydrocarbon receptor circuit. Furthermore, unlike LPS, EPS does not induce inflammatory cytokines upon injection in vivo, directly demonstrating different outcomes induced by two different TLR4 agonists. |
---|---|
MeSH term(s) | Humans ; Mice ; Animals ; Toll-Like Receptor 4/metabolism ; Bacillus subtilis ; Colitis ; Anti-Inflammatory Agents/pharmacology ; Probiotics ; Dendritic Cells |
Chemical Substances | Toll-Like Receptor 4 ; Anti-Inflammatory Agents ; TLR4 protein, human |
Language | English |
Publishing date | 2023-09-06 |
Publishing country | United States |
Document type | Journal Article ; Research Support, N.I.H., Intramural |
ZDB-ID | 3056-9 |
ISSN | 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381 |
ISSN (online) | 1550-6606 |
ISSN | 0022-1767 ; 1048-3233 ; 1047-7381 |
DOI | 10.4049/jimmunol.2200855 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ud II Zs.37: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 28: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.